ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications
Laboratory of Molecular Disease and Cell Regulation, Department of Biochemistry, School of Medicine, Gachon University, Incheon 406-840, Korea
J. Clin. Med. 2020, 9(7), 2255; https://doi.org/10.3390/jcm9072255
Received: 9 June 2020
/
Revised: 9 July 2020
/
Accepted: 15 July 2020
/
Published: 16 July 2020
(This article belongs to the Special Issue Diagnosis, Molecular Pathogenesis, and Targeted Therapies for Cholangiocarcinoma)
The erythroblastic leukemia viral oncogene homolog (ErBb) family consists of the receptor tyrosine kinases (RTK) epidermal growth factor receptor (EGFR; also called ERBB1), ERBB2, ERBB3, and ERBB4. This family is closely associated with the progression of cholangiocarcinoma (CC) through the regulation of cellular networks, which are enhanced during tumorigenesis, metastasis, and chemoresistance. Additionally, the constitutive activation of cellular signaling by the overexpression and somatic mutation-mediated alterations conferred by the ErBb family on cholangiocarcinoma and other cancers enhances tumor aggressiveness and chemoresistance by contributing to the tumor microenvironment. This review summarizes the recent findings on the molecular functions of the ErBb family and their mutations during the progression of cholangiocarcinoma. It also discusses the developments and applications of various devising strategies for targeting the ErBb family through different inhibitors in various stages of clinical trials, which are essential for improving targeted clinical therapies.
View Full-Text
Keywords:
Epidermal growth factor receptor (EGFR) family; cholangiocarcinoma; aggressiveness; mutation; chemoresistance; EGFR family-targeting inhibitors
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Jin, W. ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications. J. Clin. Med. 2020, 9, 2255. https://doi.org/10.3390/jcm9072255
AMA Style
Jin W. ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications. Journal of Clinical Medicine. 2020; 9(7):2255. https://doi.org/10.3390/jcm9072255
Chicago/Turabian StyleJin, Wook. 2020. "ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications" Journal of Clinical Medicine 9, no. 7: 2255. https://doi.org/10.3390/jcm9072255
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
